Munich Startup · Jan 2026
Founder interview covering the company mission, product focus, workflow complexity, and the rationale for building a specialized AI platform for pricing and market access.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Cellbyte is a Munich-based, seed-stage AI-native software company building a collaborative pricing and market access intelligence workspace for pharmaceutical teams. Its platform helps users research, analyze, and automate drug-launch workflows across regulatory, HTA, pricing, and internal data.
Primary product
AI-native platform for pharmaceutical Pricing & Market Access teams (Drug Explorer, Document Intelligence, Agentic Workflows, Data Vault)
Founded
2024
Headquarters
Westenriederstraße 10-12, 80331 Munich, Germany
Team size
11
Work style
Onsite
Industry
Software Development
Sub-industry
AI-native pharmaceutical pricing and market access intelligence software
0 jobs at Cellbyte
Check back later for new openings
Offices
Business model
Stage
seed
Total raised
$3.3M
Latest round
Seed · Nov 2025
Latest amount
$2.8M
Nov 2025 · Frontline Ventures
Jan 2022 · Y Combinator
Leadership
Co-founder & Co-CEO
Co-founder & Co-CEO
Co-founder & CTO
Executive Operations Lead
Founding Engineer AI & ML
Small, international, founder-led team with a strong product and sales bias; mission-driven around accelerating pharma drug launches; high-agency, fast-growing, evidence- and trust-oriented, with an office-based Munich hub and an expanding U.S. presence.
Work style
Onsite
Compensation
Public job posts mention competitive salary plus equity, with one founding engineer role advertised at €120,000–€200,000 base plus equity. Founder posts also describe tier-1 compensation, high flexibility, and meaningful equity participation; sales roles mention uncapped commission.
Benefits
Pricing
Sales-led enterprise SaaS with annual platform contracts
Differentiators
Technology
Customers
Competitors
Estimated revenue
≈$330K ARR (estimated, Sep 2025)
Estimated monthly visits
2.5K
Traffic estimate as of Jul 2026
Munich Startup · Jan 2026
Founder interview covering the company mission, product focus, workflow complexity, and the rationale for building a specialized AI platform for pricing and market access.
Cellbyte · Nov 2025
Official seed-round announcement: Cellbyte raised $2.75M led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels; the company said it had six-figure ARR and contracts with major pharma customers.
FinSMEs · Nov 2025
Independent funding coverage confirming the $2.75M seed round, the lead investor, and the company’s pharma drug-launch product focus.
Tech Funding News · Nov 2025
Profiles Cellbyte’s AI platform for pharma launch workflows, the seed round, and claims about Bayer customers, market access, and launch-timeline reduction.
PharmaTimes · Nov 2025
Pharma industry coverage of the seed round, customer traction, and the company’s AI platform for market access and launch planning.